Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Protokylol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 15/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.76 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.76 |
| ▸ | ADRA1D | P25100 | 11/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.76 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.76 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protokylol SCHEMBL210099 | 0.99 | ADRB2 (0.74) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Protokylol SCHEMBL523029 | 0.98 | ADRB2 (0.73) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11191804 | 0.87 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11670365 | 0.87 | ADRB3 (0.70) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL7154320 | 0.85 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL7154315 | 0.85 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL8305498 | 0.82 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL30051139 | 0.82 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL8305494 | 0.82 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL10446972 | 0.82 | ADRB2 (0.64) | ADRB2ADRB1ADRB3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2043 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| US-20240398819-A1 | UTILITY OF VITAMIN D, FOLIC ACID AND NADH TO IMPROVE LIGAMENT INJURY PREVENTION CHARACTERISTICS | RHODE ISLAND HOSPITAL | 2024-12-05 | — | — | US | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| EP-1169294-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5626854-A | XANTHINE OR B-ADRENERGIC STIMULANT | KAO CORPORATION (JP) | 1997-05-06 | — | — | US | claimed |
| US-RE29875-E | THEOPHYLLINE SOLUBILIZED BY GLYCERYL GUAIACOLATE, POTASSIUM GUAIACOL SULFONATE OR GUAIACOL | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | claimed |